Oklahoma judge Thad Balkman is expected to rule on Monday on whether Johnson & Johnson is liable in an opioid lawsuit brought by the state’s attorney general. The drugmaker could be forced to pay $17 billion if it is found liable for fueling the opioid epidemic. The results could also have an impact on thousands of other cases. (Reuters)

Pfizer is planning to invest $500 million in a gene-therapy manufacturing facility in North Carolina. It would create 300 jobs and allow the drugmaker to increase its number of gene-therapy treatments. Pfizer has three clinical gene-therapy programs and 10 preclinical programs. (Bloomberg)

Overdose deaths may be on the decline overall, but designer drugs are resulting in an increase in overdose deaths on the West Coast. Former Food and Drug Administration Commissioner Scott Gottlieb pointed toward speedballs, which is cocaine cut with fentanyl, and goofballs, a combination of methamphetamine and fentanyl, as new contributors to overdoses. (CNBC)

AstraZeneca’s Imfinzi combination late-stage clinical trial for advanced lung cancer has failed. The treatment of Imfinzi combined with tremelimumab was unable to extend the overall survival rate of patients with stage IV lung cancer. The combination is being tested for bladder and blood cancers, as well. (Endpoints)

Fitbit has partnered with the government of Singapore to offer hundreds of thousands of fitness trackers to its citizens. The partnership could help make Singaporeans healthier by combating diseases on the rise there, like diabetes and heart disease. To receive a device, users must register for Fitbit Inspire, which costs $10 a month. (CNBC)